Company news
Arvinas, Inc. (NASDAQ:ARVN) news
Every Arvinas, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 4, 2026
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for...
May 4, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 1, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Di...
March 18, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s...
March 11, 2026
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
Arvinas : Initial Statement of Beneficial Ownership (Form 3)
February 18, 2026
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 17, 2026
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 12, 2026
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Gl...
December 6, 2025
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer ...
November 24, 2025
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
Arvinas to Participate in Upcoming Investor Conferences
November 3, 2025
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
November 3, 2025
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
October 29, 2025
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at t...
October 24, 2025
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Mole...
October 22, 2025
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2...
October 20, 2025
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Cong...
October 13, 2025
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress o...
October 5, 2025
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Move...
October 1, 2025
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
September 17, 2025
Cascade Prodrug Inc. Appoints Industry Veterans Manuel (Manny) Litchman and Andres Gutierrez to Board of Directors
August 28, 2025
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
August 8, 2025
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2025
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
July 9, 2025
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
June 13, 2025
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or M...
June 6, 2025
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
June 5, 2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Bre...
May 31, 2025
Arvinas to Present at Jefferies Global Healthcare Conference
May 30, 2025
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 1, 2025
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Resear...
April 28, 2025
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 28, 2025
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical O...
April 23, 2025
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Me...
April 21, 2025
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central a...
April 4, 2025
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
March 27, 2025
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
March 11, 2025
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 3, 2025
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Pr...
January 10, 2025